H19 (H19 imprinted maternally expressed transcript) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: H19 (H19 imprinted maternally expressed transcript) Rattus norvegicus
Analyze
Symbol: H19
Name: H19 imprinted maternally expressed transcript
RGD ID: 2775
Description: Enables miRNA inhibitor activity via base-pairing. Involved in several processes, including negative regulation of gene expression; negative regulation of programmed cell death; and positive regulation of cardiac muscle cell apoptotic process. Predicted to be part of RISC complex. Used to study acute myocardial infarction; dilated cardiomyopathy; middle cerebral artery infarction; and myocardial infarction. Biomarker of hepatocellular carcinoma; middle cerebral artery infarction; pre-eclampsia; and transitional cell carcinoma. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); cerebral infarction; mature T-cell and NK-cell lymphoma; teratoma; and urinary system cancer (multiple). Orthologous to human H19 (H19 imprinted maternally expressed transcript); INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; 5-aza-2'-deoxycytidine.
Type: ncrna (Ensembl: protein-coding)
RefSeq Status: VALIDATED
Previously known as: ASM; ASM1; D11S813E; H19 fetal liver mRNA; H19 fetal liver mRNA (mapped); H19, imprinted maternally expressed transcript; H19, imprinted maternally expressed transcript (non-protein coding); H19_mapped
RGD Orthologs
Human
Mouse
Alliance Orthologs
More Info more info ...
Candidate Gene For: Hcar4
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81207,160,175 - 207,162,851 (-)NCBIGRCr8GRCr8GRCr8
mRatBN7.21197,730,698 - 197,733,374 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1197,730,698 - 197,733,134 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1206,103,477 - 206,106,153 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01213,189,309 - 213,191,985 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01205,863,465 - 205,866,141 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01215,744,404 - 215,747,080 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_5.01222,639,223 - 222,641,899 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41202,822,925 - 202,825,601 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1195,348,096 - 195,350,772 (-)NCBICelera
Cytogenetic Map1q41NCBI
JBrowse:




Disease Annotations     Click to see Annotation Detail View
acute myocardial infarction  (IMP)
Animal Hepatitis  (ISO)
aortic dissection  (ISO)
arteriosclerosis obliterans  (ISO)
atherosclerosis  (ISO)
atrial fibrillation  (ISO)
Beckwith-Wiedemann syndrome  (ISO)
Birth Weight  (ISO)
breast adenocarcinoma  (ISO)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
bronchopulmonary dysplasia  (ISO)
Carcinogenesis  (ISO)
Cardiac Fibrosis  (IEP)
Cardiomegaly  (ISO)
Carotid Artery Injuries  (IEP)
cerebral infarction  (ISO)
cervix carcinoma  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
congestive heart failure  (ISO)
coronary artery disease  (ISO)
Desbuquois dysplasia  (ISO)
Diabetic Cardiomyopathies  (IMP,ISO)
Diabetic Foot  (ISO)
dilated cardiomyopathy  (IMP)
endometrial carcinoma  (ISO)
endometrial hyperplasia  (ISO)
Endometrial Neoplasms  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Liver Neoplasms  (IDA,ISO)
Experimental Mammary Neoplasms  (IEP)
Germ Cell and Embryonal Neoplasms  (ISO)
heart cancer  (ISO)
hepatocellular carcinoma  (IEP)
lung non-small cell carcinoma  (ISO)
mature T-cell and NK-cell lymphoma  (ISO)
middle cerebral artery infarction  (IEP,IMP,ISO)
multiple myeloma  (ISO)
myocardial infarction  (IMP)
Myocardial Reperfusion Injury  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplastic Cell Transformation  (ISO)
nephroblastoma  (ISO)
nicotine dependence  (ISO)
Ovarian Neoplasms  (ISO)
ovary epithelial cancer  (ISO)
pre-eclampsia  (IEP,ISO)
Pulmonary Arterial Hypertension  (IEP,ISO)
renal Wilms' tumor  (ISO)
retinal ischemia  (ISO)
severe pre-eclampsia  (ISO)
Silver-Russell syndrome  (ISO)
Silver-Russell Syndrome 1  (ISO)
small artery occlusion  (ISO)
teratocarcinoma  (ISO)
teratoma  (ISO)
transitional cell carcinoma  (IEP)
type 2 diabetes mellitus  (ISO)
urinary bladder cancer  (ISO)
uterine cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)
Uterine Neoplasms  (ISO)
Wilms Tumor 2  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(1->4)-beta-D-glucan  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-methylcholine  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-sulfonyldiphenol  (ISO)
5-aza-2'-deoxycytidine  (EXP,ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
acetamide  (EXP)
acrylamide  (EXP)
actinomycin D  (ISO)
aflatoxin B1  (EXP,ISO)
all-trans-retinoic acid  (ISO)
antirheumatic drug  (ISO)
Aroclor 1254  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
astragaloside IV  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
butanal  (ISO)
Butylbenzyl phthalate  (ISO)
cadmium atom  (ISO)
cantharidin  (ISO)
CGP 52608  (ISO)
CHIR 99021  (ISO)
chlorpyrifos-methyl  (ISO)
choline  (ISO)
chrysene  (ISO)
cisplatin  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
Cuprizon  (EXP)
curcumin  (EXP,ISO)
cyclosporin A  (ISO)
D-glucose  (ISO)
DDE  (EXP,ISO)
dexamethasone  (EXP,ISO)
dibenzo[a,l]pyrene  (ISO)
dicrotophos  (ISO)
diethylstilbestrol  (EXP)
doxorubicin  (EXP,ISO)
ethanol  (ISO)
fipronil  (ISO)
folic acid  (ISO)
fonofos  (ISO)
formaldehyde  (ISO)
furan  (EXP)
glyphosate  (EXP)
GW 4064  (ISO)
hydrogen peroxide  (ISO)
indometacin  (ISO)
isoprenaline  (EXP,ISO)
L-methionine  (ISO)
lead(0)  (ISO)
lidocaine  (EXP)
luzindole  (ISO)
malathion  (ISO)
melatonin  (EXP)
melittin  (ISO)
metformin  (EXP,ISO)
methylmercury chloride  (EXP)
monocrotaline  (EXP,ISO)
N,N-diethyl-m-toluamide  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-nitrosodiethylamine  (ISO)
nickel atom  (ISO)
nickel subsulfide  (EXP)
Nutlin-3  (ISO)
okadaic acid  (ISO)
ozone  (ISO)
paracetamol  (ISO)
parathion  (ISO)
pentanal  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenobarbital  (ISO)
phytoestrogen  (ISO)
pirinixic acid  (ISO)
progesterone  (ISO)
propanal  (ISO)
propofol  (ISO)
raloxifene  (ISO)
resveratrol  (EXP,ISO)
serpentine asbestos  (ISO)
silicon dioxide  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (ISO)
Soman  (EXP)
streptozocin  (EXP)
tamoxifen  (EXP,ISO)
terbufos  (ISO)
tetrachloromethane  (EXP,ISO)
triclosan  (ISO)
valproic acid  (ISO)
vinclozolin  (ISO)
zearalenone  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

References

References - curated
# Reference Title Reference Citation
1. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Adriaenssens E, etal., Am J Pathol. 1998 Nov;153(5):1597-607.
2. Assessment of Cell-Free Long Non-Coding RNA-H19 and miRNA-29a, miRNA-29b Expression and Severity of Diabetes. Alfaifi M, etal., Diabetes Metab Syndr Obes. 2020 Oct 14;13:3727-3737. doi: 10.2147/DMSO.S273586. eCollection 2020.
3. Gene expression in the bladder carcinoma rat model. Ariel I, etal., Mol Carcinog. 2004 Oct;41(2):69-76.
4. Hormonal regulation of H19 gene expression in prostate epithelial cells. Berteaux N, etal., J Endocrinol. 2004 Oct;183(1):69-78.
5. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Bhatti P, etal., Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2007-11.
6. Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. Cai B, etal., J Pineal Res. 2016 Aug;61(1):82-95. doi: 10.1111/jpi.12331. Epub 2016 Apr 29.
7. LncRNA H19/miR-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin. Cao L, etal., Int Immunopharmacol. 2019 Jul;72:496-503. doi: 10.1016/j.intimp.2019.04.042. Epub 2019 May 1.
8. LncRNA H19 is involved in myocardial ischemic preconditioning via increasing the stability of nucleolin protein. Chen C, etal., J Cell Physiol. 2020 Sep;235(9):5985-5994. doi: 10.1002/jcp.29524. Epub 2020 Jan 24.
9. Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Chen CL, etal., Clin Cancer Res. 2000 Feb;6(2):474-9.
10. Hepatocellular carcinomas of the albumin SV40 T-antigen transgenic rat display fetal-like re-expression of lgf2 and deregulation of H19. Czarny MJ, etal., Mol Carcinog. 2007 Sep;46(9):747-57.
11. The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Elkin M, etal., Carcinogenesis. 1998 Dec;19(12):2095-9.
12. Identification of novel differentially expressed genes by the effect of a high-fat n-6 diet in experimental breast cancer. Escrich E, etal., Mol Carcinog. 2004 Jun;40(2):73-8.
13. LncRNA H19 Aggravates Cerebral Ischemia/Reperfusion Injury by Functioning as a ceRNA for miR-19a-3p to Target PTEN. Gao N, etal., Neuroscience. 2020 Jun 15;437:117-129. doi: 10.1016/j.neuroscience.2020.04.020. Epub 2020 Apr 24.
14. Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome. Gaston V, etal., Eur J Hum Genet. 2001 Jun;9(6):409-18.
15. Long noncoding RNA dysregulation in ischemic heart failure. Greco S, etal., J Transl Med. 2016 Jun 18;14(1):183. doi: 10.1186/s12967-016-0926-5.
16. LncRNA H19 Drives Proliferation of Cardiac Fibroblasts and Collagen Production via Suppression of the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β Axis. Guo F, etal., Mol Cells. 2022 Mar 31;45(3):122-133. doi: 10.14348/molcells.2021.0066.
17. LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner. Han Y, etal., Mol Cell Biochem. 2021 Mar;476(3):1387-1400. doi: 10.1007/s11010-020-03998-y. Epub 2021 Jan 3.
18. Relationship between Long Noncoding RNA H19 Polymorphisms and Risk of Coronary Artery Disease in a Chinese Population: A Case-Control Study. Hu WN, etal., Dis Markers. 2020 May 10;2020:9839612. doi: 10.1155/2020/9839612. eCollection 2020.
19. Long Noncoding RNA-H19 Contributes to Atherosclerosis and Induces Ischemic Stroke via the Upregulation of Acid Phosphatase 5. Huang Y, etal., Front Neurol. 2019 Feb 4;10:32. doi: 10.3389/fneur.2019.00032. eCollection 2019.
20. LncRNA H19 interacted with miR-130a-3p and miR-17-5p to modify radio-resistance and chemo-sensitivity of cardiac carcinoma cells. Jia J, etal., Cancer Med. 2019 Apr;8(4):1604-1618. doi: 10.1002/cam4.1860. Epub 2019 Mar 6.
21. Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin. Kawakami T, etal., Oncogene. 2006 Jun 1;25(23):3225-36. Epub 2006 Jan 23.
22. H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury. Kim DK, etal., J Clin Invest. 1994 Jan;93(1):355-60.
23. Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II. Kim SJ, etal., Biochim Biophys Acta. 2002 Apr 24;1586(3):307-15.
24. Imprinted gene expression in the rat embryo-fetal axis is altered in response to periconceptional maternal low protein diet. Kwong WY, etal., Reproduction. 2006 Aug;132(2):265-77.
25. Direct relationship between the expression of tumor suppressor H19 mRNA and c-mos proto-oncogene during myogenesis. Leibovitch MP, etal., Oncogene. 1995 Jan 19;10(2):251-60.
26. Long noncoding RNA H19 acts as a miR-29b sponge to promote wound healing in diabetic foot ulcer. Li B, etal., FASEB J. 2021 Jan;35(1):e20526. doi: 10.1096/fj.201900076RRRRR. Epub 2020 Nov 10.
27. Long non-coding RNA H19 promotes leukocyte inflammation in ischemic stroke by targeting the miR-29b/C1QTNF6 axis. Li G, etal., CNS Neurosci Ther. 2022 Jun;28(6):953-963. doi: 10.1111/cns.13829. Epub 2022 Mar 24.
28. PFOS-induced placental cell growth inhibition is partially mediated by lncRNA H19 through interacting with miR-19a and miR-19b. Li J, etal., Chemosphere. 2020 Dec;261:127640. doi: 10.1016/j.chemosphere.2020.127640. Epub 2020 Jul 13.
29. lncRNA H19 Alleviated Myocardial I/RI via Suppressing miR-877-3p/Bcl-2-Mediated Mitochondrial Apoptosis. Li X, etal., Mol Ther Nucleic Acids. 2019 Sep 6;17:297-309. doi: 10.1016/j.omtn.2019.05.031. Epub 2019 Jun 14.
30. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Li X, etal., Sci Rep. 2016 Oct 31;6:36340. doi: 10.1038/srep36340.
31. Effect of lncRNA H19 on the apoptosis of vascular endothelial cells in arteriosclerosis obliterans via the NF-κB pathway. Li ZF, etal., Eur Rev Med Pharmacol Sci. 2019 May;23(10):4491-4497. doi: 10.26355/eurrev_201905_17961.
32. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Liu L, etal., Cardiovasc Res. 2016 Jul 1;111(1):56-65. doi: 10.1093/cvr/cvw078. Epub 2016 Apr 15.
33. The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. Lottin S, etal., Eur J Cancer. 2005 Jan;41(1):168-77.
34. Methylation pattern of H19 exon 1 is closely related to preeclampsia and trophoblast abnormalities. Lu L, etal., Int J Mol Med. 2014 Sep;34(3):765-71. doi: 10.3892/ijmm.2014.1816. Epub 2014 Jun 23.
35. LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression. Luo R, etal., Kaohsiung J Med Sci. 2021 Feb;37(2):101-110. doi: 10.1002/kjm2.12302. Epub 2020 Oct 6.
36. Changes in the DNA methylation profile of the rat H19 gene upstream region during development and transgenic hepatocarcinogenesis and its role in the imprinted transcriptional regulation of the H19 gene. Manoharan H, etal., Mol Carcinog 2004 Sep;41(1):1-16.
37. Methylation imprinting of H19 and SNRPN genes in human benign ovarian teratomas. Miura K, etal., Am J Hum Genet. 1999 Nov;65(5):1359-67.
38. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
39. Online Mendelian Inheritance in Man, OMIM (TM). Online Mendelian Inheritance in Man, OMIM (TM).
40. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Pan JX, Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):322-328.
41. Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Pan Y, etal., Clin Chim Acta. 2018 May;480:199-205. doi: 10.1016/j.cca.2018.02.019. Epub 2018 Feb 19.
42. Effect of tamoxifen treatment on global and insulin-like growth factor 2-H19 locus-specific DNA methylation in rat spermatozoa and its association with embryo loss. Pathak S, etal., Fertil Steril. 2009 May;91(5 Suppl):2253-63. Epub 2008 Sep 7.
43. Mesenchymal-epithelial transition in the developing metanephric kidney: gene expression study by differential display. Plisov SY, etal., Genesis. 2000 May;27(1):22-31.
44. LncRNA H19 serves as a ceRNA and participates in non-small cell lung cancer development by regulating microRNA-107. Qian B, etal., Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5946-5953. doi: 10.26355/eurrev_201809_15925.
45. LncRNA H19 regulates smooth muscle cell functions and participates in the development of aortic dissection through sponging miR-193b-3p. Ren M, etal., Biosci Rep. 2021 Jan 29;41(1):BSR20202298. doi: 10.1042/BSR20202298.
46. Long non-coding RNA H19 expression and functional polymorphism rs217727 are linked to increased ischemic stroke risk. Rezaei M, etal., BMC Neurol. 2021 Feb 4;21(1):54. doi: 10.1186/s12883-021-02081-3.
47. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
48. Comprehensive gene review and curation RGD comprehensive gene curation
49. Expression of IGF-II and H19 mRNA in the neonatal rat during normal maturation and after dexamethasone administration. Senior PV, etal., J Mol Endocrinol 1996 Dec;17(3):217-23.
50. Metformin exhibits its therapeutic effect in the treatment of pre-eclampsia via modulating the Met/H19/miR-148a-5p/P28 and Met/H19/miR-216-3p/EBI3 signaling pathways. Shu C, etal.
51. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. Sidi AA, etal., J Urol. 2008 Dec;180(6):2379-83. Epub 2008 Oct 31.
52. Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling. Song Z, etal., Toxicol Appl Pharmacol. 2019 Feb 1;364:45-54. doi: 10.1016/j.taap.2018.12.002. Epub 2018 Dec 5.
53. LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension. Su H, etal., Respir Res. 2018 Dec 14;19(1):254. doi: 10.1186/s12931-018-0956-z.
54. Downregulation of lncRNA H19 alleviates atherosclerosis through inducing the apoptosis of vascular smooth muscle cells. Sun H, etal., Mol Med Rep. 2020 Oct;22(4):3095-3102. doi: 10.3892/mmr.2020.11394. Epub 2020 Jul 31.
55. Gene-based anchoring of the rat genetic linkage and cytogenetic maps: new regional localizations, orientation of the linkage groups, and insights into mammalian chromosome evolution. Szpirer C, etal., Mamm Genome 1998 Sep;9(9):721-34
56. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Takai D, etal., Hum Mol Genet. 2001 Nov 1;10(23):2619-26.
57. H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Tanos V, etal., Int J Gynecol Cancer. 2004 May-Jun;14(3):521-5.
58. Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. Tao H, etal., Cardiovasc Pathol. 2016 Sep-Oct;25(5):381-9. doi: 10.1016/j.carpath.2016.05.005. Epub 2016 Jun 2.
59. Polymorphisms in the H19 gene and the risk of bladder cancer. Verhaegh GW, etal., Eur Urol. 2008 Nov;54(5):1118-26. Epub 2008 Feb 4.
60. LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. Wan P, etal., Cell Death Differ. 2020 Jan;27(1):176-191. doi: 10.1038/s41418-019-0351-4. Epub 2019 May 24.
61. Long noncoding RNA H19 suppresses cardiac hypertrophy through the MicroRNA-145-3p/SMAD4 axis. Wang H, etal., Bioengineered. 2022 Feb;13(2):3826-3839. doi: 10.1080/21655979.2021.2017564.
62. Long Non-coding RNA H19 Induces Cerebral Ischemia Reperfusion Injury via Activation of Autophagy. Wang J, etal., Aging Dis. 2017 Feb 1;8(1):71-84. doi: 10.14336/AD.2016.0530. eCollection 2017 Feb.
63. Exosome-transported lncRNA H19 regulates insulin-like growth factor-1 via the H19/let-7a/insulin-like growth factor-1 receptor axis in ischemic stroke. Wang J, etal., Neural Regen Res. 2023 Jun;18(6):1316-1320. doi: 10.4103/1673-5374.357901.
64. Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization. Wang J, etal., Stroke. 2017 Aug;48(8):2211-2221. doi: 10.1161/STROKEAHA.117.017387. Epub 2017 Jun 19.
65. Identifying Involvement of H19-miR-675-3p-IGF1R and H19-miR-200a-PDCD4 in Treating Pulmonary Hypertension with Melatonin. Wang R, etal., Mol Ther Nucleic Acids. 2018 Dec 7;13:44-54. doi: 10.1016/j.omtn.2018.08.015. Epub 2018 Aug 24.
66. LncRNA H19 inhibits ER stress induced apoptosis and improves diabetic cardiomyopathy by regulating PI3K/AKT/mTOR axis. Wang S, etal., Aging (Albany NY). 2022 Aug 30;14(16):6809-6828. doi: 10.18632/aging.204256. Epub 2022 Aug 30.
67. Blocking lncRNA H19-miR-19a-Id2 axis attenuates hypoxia/ischemia induced neuronal injury. Xiao Z, etal., Aging (Albany NY). 2019 Jun 5;11(11):3585-3600. doi: 10.18632/aging.101999.
68. Overexpression of long non-coding RNA H19 promotes invasion and autophagy via the PI3K/AKT/mTOR pathways in trophoblast cells. Xu J, etal., Biomed Pharmacother. 2018 May;101:691-697. doi: 10.1016/j.biopha.2018.02.134. Epub 2018 Mar 22.
69. Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1 expression in ApoE knockout mice. Yang Y, etal., Aging (Albany NY). 2019 Nov 22;11(22):10016-10030. doi: 10.18632/aging.102388. Epub 2019 Nov 22.
70. Knockdown of lncRNA H19 alleviates ox-LDL-induced HCAECs inflammation and injury by mediating miR-20a-5p/HDAC4 axis. Yang Y, etal., Inflamm Res. 2022 Sep;71(9):1109-1121. doi: 10.1007/s00011-022-01604-z. Epub 2022 Jul 19.
71. The H19 locus acts in vivo as a tumor suppressor. Yoshimizu T, etal., Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12417-22. Epub 2008 Aug 21.
72. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A. Zhang BF, etal., J Cell Mol Med. 2020 Jan;24(1):1099-1115. doi: 10.1111/jcmm.14846. Epub 2019 Nov 21.
73. Correlation between lncRNA H19 rs2839698 polymorphism and susceptibility to NK / T cell lymphoma in Chinese population. Zhang J, etal., J BUON. 2021 Mar-Apr;26(2):587-591.
74. Mechanism of lncRNA H19 in Regulating Pulmonary Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia Newborn Mice. Zhang L, etal., Am J Perinatol. 2022 Jul;39(10):1089-1096. doi: 10.1055/s-0040-1721498. Epub 2020 Dec 7.
75. The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy. Zhang Y, etal., Oncotarget. 2017 Apr 25;8(17):28588-28594. doi: 10.18632/oncotarget.15544.
76. LncRNA H19 abrogates the protective effects of curcumin on rat carotid balloon injury via activating Wnt/β-catenin signaling pathway. Zhou F, etal., Eur J Pharmacol. 2021 Nov 5;910:174485. doi: 10.1016/j.ejphar.2021.174485. Epub 2021 Sep 3.
77. LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Zhuo C, etal., Oncotarget. 2017 Jan 3;8(1):1429-1437. doi: 10.18632/oncotarget.13637.
Additional References at PubMed
PMID:9203585   PMID:9294195   PMID:9502736   PMID:12477932   PMID:15094229   PMID:19337063   PMID:19762426   PMID:26038570   PMID:27071665   PMID:27350269   PMID:28063931   PMID:28362134  
PMID:28447380   PMID:28564591   PMID:28867213   PMID:29636074   PMID:29795132   PMID:30312698   PMID:30551879   PMID:30575922   PMID:30628827   PMID:32114772   PMID:32198976   PMID:32301281  
PMID:32319634   PMID:32648622   PMID:32698630   PMID:33111281   PMID:33197240   PMID:33230843   PMID:33410377   PMID:33608066   PMID:33629893   PMID:33744742   PMID:33785379   PMID:34015968  
PMID:34137055   PMID:34311444   PMID:34436746   PMID:34494412   PMID:34818452   PMID:34923106   PMID:34999183   PMID:35603469   PMID:35781830   PMID:36394706   PMID:36418735   PMID:37310354  
PMID:37409531   PMID:37814860   PMID:37848100   PMID:38685675   PMID:39214267  


Genomics

Comparative Map Data
H19
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81207,160,175 - 207,162,851 (-)NCBIGRCr8GRCr8GRCr8
mRatBN7.21197,730,698 - 197,733,374 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1197,730,698 - 197,733,134 (-)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx1206,103,477 - 206,106,153 (-)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01213,189,309 - 213,191,985 (-)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01205,863,465 - 205,866,141 (-)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.01215,744,404 - 215,747,080 (-)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_5.01222,639,223 - 222,641,899 (-)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.41202,822,925 - 202,825,601 (-)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera1195,348,096 - 195,350,772 (-)NCBICelera
Cytogenetic Map1q41NCBI
H19
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38111,995,176 - 2,001,266 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl111,995,165 - 2,004,552 (-)Ensemblhg38GRCh38
GRCh37112,016,406 - 2,022,496 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36111,972,982 - 1,975,641 (-)NCBIBuild 36Build 36hg18NCBI36
Celera112,055,536 - 2,058,195 (-)NCBICelera
Cytogenetic Map11p15.5NCBI
HuRef111,807,445 - 1,810,104 (-)NCBIHuRef
CHM1_1112,015,226 - 2,017,885 (-)NCBICHM1_1
T2T-CHM13v2.0112,082,853 - 2,088,943 (-)NCBIT2T-CHM13v2.0
H19
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm397142,129,267 - 142,131,883 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl7142,129,262 - 142,133,957 (-)EnsemblGRCm39 EnsemblGRCm39
GRCm387142,575,530 - 142,578,146 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl7142,575,529 - 142,578,143 (-)Ensemblmm10GRCm38
MGSCv377149,761,437 - 149,764,051 (-)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv367142,384,922 - 142,387,536 (-)NCBIMGSCv36mm8
Celera7142,331,374 - 142,333,988 (-)NCBICelera
Cytogenetic Map7F5NCBI
cM Map787.97NCBI

Variants

.
Variants in H19
7 total Variants

QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1160111531262090437Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1160573753266453731Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1186658830266453731Rat
1354653Despr9Despair related QTL 90.00019locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)1177339686222339686Rat
2293673Bss27Bone structure and strength QTL 2718.630.0001femur morphology trait (VT:0000559)femur midshaft cortical cross-sectional area (CMO:0001663)1181059071226059071Rat
2293677Bss41Bone structure and strength QTL 419.380.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1181059071226059071Rat
1549830Bss1Bone structure and strength QTL 14.8femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1182039247227039247Rat
70163Bw20Body weight QTL 205.1body mass (VT:0001259)body weight (CMO:0000012)1183564652228564652Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1205233991267096252Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1186658830266453731Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1205233991267096252Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1176288899270518180Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1193964073238964073Rat
1354636Lmblg1Limb length QTL 16.4tibia length (VT:0004357)tibia length (CMO:0000450)1160573753210707719Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1162548015270518180Rat
2293689Bss47Bone structure and strength QTL 477.250.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra trabecular cross-sectional area (CMO:0001692)1181059071226059071Rat
152025235Bw194Body weight QTL 1944.86body mass (VT:0001259)1132966869252856240Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1205233991267096252Rat
61341Bp26Blood pressure QTL 26arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1139442053223964440Rat
1598853Memor3Memory QTL 34.5exploratory behavior trait (VT:0010471)total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443)1152919152268496042Rat
1354634Kidm12Kidney mass QTL 123.9kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)1160573753210707719Rat
4889428Stresp24Stress response QTL 240.05heart pumping trait (VT:2000009)absolute change in electrocardiographic low frequency R-R spectral component to high frequency R-R spectral component ratio (CMO:0002162)1165278545210278545Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1160111531262090437Rat
2293693Bss22Bone structure and strength QTL 2233.520.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1181059071226059071Rat
1358902Bw47Body weight QTL 471.67body mass (VT:0001259)body weight (CMO:0000012)199645382221502378Rat
2300161Bmd43Bone mineral density QTL 438.40.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1181059071226059071Rat
1300145Rf7Renal function QTL 72.96urine creatinine amount (VT:0010540)urine creatinine level (CMO:0000125)1194575422239575422Rat
61347Bp197Blood pressure QTL 1974.2arterial blood pressure trait (VT:2000000)blood pressure measurement (CMO:0000003)1168063662213063662Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1193400541238400541Rat
61348Bp30Blood pressure QTL 302.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1159894717207261263Rat
2303622Vencon6Ventilatory control QTL 60.001respiration trait (VT:0001943)respiration rate (CMO:0000289)1163992710208992710Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1200449456256003563Rat
631214Bw61Body weight QTL613.40.0001intramuscular adipose amount (VT:0010044)intramuscular fat area (CMO:0001162)1182535316227535316Rat
7771612Cm80Cardiac mass QTL 808.4heart left ventricle mass (VT:0007031)heart left ventricle weight (CMO:0000776)1146080545243492863Rat
731168Bp154Blood pressure QTL 1543.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1103779152223964440Rat
631205Bp196Blood pressure QTL 19640.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)198879955208479939Rat
2300174Bmd42Bone mineral density QTL 428.40.0001lumbar vertebra mineral mass (VT:0010511)bone mineral density (CMO:0001226)1181059071226059071Rat
737828Hcas3Hepatocarcinoma susceptibility QTL 34.9liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)1153679879232414077Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1160573753266453731Rat
1358886Bp260Blood pressure QTL 2603.67arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1160574007235238518Rat
2293654Bss30Bone structure and strength QTL 3032.650.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1181059071226059071Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1160111426262090599Rat
2300187Bmd41Bone mineral density QTL 418.90.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1181059071226059071Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1202543537247543537Rat
1359018Hrtrt20Heart rate QTL 203.08heart pumping trait (VT:2000009)heart rate (CMO:0000002)1194786607207590403Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1154961463266453731Rat
70209Niddm23Non-insulin dependent diabetes mellitus QTL 232.82blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1162753891207753891Rat
1358292Cm37Cardiac mass QTL 376.28e-07heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1205674651250674651Rat
634312Bp143Blood pressure QTL 14330.0002arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1203300512229359342Rat
1358294Bw37Body weight QTL 3750.000011body mass (VT:0001259)body weight (CMO:0000012)1180739993225739993Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)151941022208479811Rat
724559Pancm1Pancreatic morphology QTL 17.1islet of Langerhans morphology trait (VT:0005215)pancreatic islet damage composite score (CMO:0001156)1191190115223964326Rat
2312420Pur17Proteinuria QTL 177.10.0001urine protein amount (VT:0005160)urine total protein excretion rate (CMO:0000756)1172718770228180370Rat
10059600Bp378Blood pressure QTL 3783.080.05arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1186298393231298393Rat
1354591Cm36Cardiac mass QTL 364.1heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1111949780210707719Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)134565911208798288Rat
631260Tcas2Tongue tumor susceptibility QTL 24.93tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)1201915593208479939Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1194786607262083703Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1188241285250779312Rat
724562Rends1Renal damage susceptibility QTL 10.05kidney glomerulus integrity trait (VT:0010546)index of glomerular damage (CMO:0001135)1139442053223964440Rat
1300168Bp170Blood pressure QTL 1702.76arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1192995199237995199Rat
61403Niddm4Non-insulin dependent diabetes mellitus QTL 4blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1201464383246464383Rat
2292222Bp307Blood pressure QTL 3073.060.0014arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1186298393231298393Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1186298393231298393Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1203675682248675682Rat
1354615Cm32Cardiac mass QTL 325.2heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)1111949780210707719Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1205674651250674651Rat
1600380Niddm70Non-insulin dependent diabetes mellitus QTL 703.10.0008blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1185979875230979875Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1160573753266453731Rat
1582206Kidm33Kidney mass QTL 336.9kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1197807365233480676Rat
1354620Kidm19Kidney mass QTL 194kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1160573753210707719Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1193400541238400541Rat
634338Hcar4Hepatocarcinoma resistance QTL 44.6liver integrity trait (VT:0010547)liver tumorous lesion number to liver area ratio (CMO:0001210)1202851915223964440Rat
6480777Insul17Insulin level QTL 173.86blood insulin amount (VT:0001560)blood insulin level area under curve (AUC) (CMO:0000351)1206690418207509562Rat
6480783Insul19Insulin level QTL 194.33blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1203300512213659238Rat
1354618Kidm15Kidney mass QTL 155kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)1165707719210707719Rat
6903303Scl34Serum cholesterol QTL 342.50.0033blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)1173363824227535316Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1207099883252099883Rat
2293083Iddm25Insulin dependent diabetes mellitus QTL 254.18blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1191260175236260175Rat
1354606Bp246Blood pressure QTL 2463.6arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)1111949780228180370Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1185857683270518180Rat
2325727Pia41Pristane induced arthritis QTL 41joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1188241285233241285Rat
1354602Bw35Body weight QTL 3512.2body mass (VT:0001259)body weight (CMO:0000012)1160573753210707719Rat

Markers in Region
H19  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,730,795 - 197,730,995 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,502 - 215,744,701NCBIRnor6.0
Rnor_5.01222,639,321 - 222,639,520UniSTSRnor5.0
RGSC_v3.41202,823,023 - 202,823,222UniSTSRGSC3.4
Celera1195,348,194 - 195,348,393UniSTS
Cytogenetic Map1q41UniSTS
RH128414  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,730,747 - 197,730,931 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,454 - 215,744,637NCBIRnor6.0
Rnor_5.01222,639,273 - 222,639,456UniSTSRnor5.0
RGSC_v3.41202,822,975 - 202,823,158UniSTSRGSC3.4
Celera1195,348,146 - 195,348,329UniSTS
Cytogenetic Map1q41UniSTS
UniSTS:143296  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,730,698 - 197,730,986 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,405 - 215,744,692NCBIRnor6.0
Rnor_5.01222,639,224 - 222,639,511UniSTSRnor5.0
RGSC_v3.41202,822,926 - 202,823,213UniSTSRGSC3.4
Celera1195,348,097 - 195,348,384UniSTS
Cytogenetic Map1q41UniSTS
UniSTS:265459  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,730,830 - 197,730,993 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,537 - 215,744,699NCBIRnor6.0
Rnor_5.01222,639,356 - 222,639,518UniSTSRnor5.0
RGSC_v3.41202,823,058 - 202,823,220UniSTSRGSC3.4
Celera1195,348,229 - 195,348,391UniSTS
Cytogenetic Map1q41UniSTS
UniSTS:265491  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr81207,160,624 - 207,160,986 (+)Marker Load Pipeline
mRatBN7.21197,731,147 - 197,731,509 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,854 - 215,745,215NCBIRnor6.0
Rnor_5.01222,639,673 - 222,640,034UniSTSRnor5.0
RGSC_v3.41202,823,375 - 202,823,736UniSTSRGSC3.4
Celera1195,348,546 - 195,348,907UniSTS
Cytogenetic Map1q41UniSTS
UniSTS:265492  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr81207,160,220 - 207,160,938 (+)Marker Load Pipeline
mRatBN7.21197,730,743 - 197,731,461 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,450 - 215,745,167NCBIRnor6.0
Rnor_5.01222,639,269 - 222,639,986UniSTSRnor5.0
RGSC_v3.41202,822,971 - 202,823,688UniSTSRGSC3.4
Celera1195,348,142 - 195,348,859UniSTS
Cytogenetic Map1q41UniSTS
H19  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,732,669 - 197,733,352 (+)MAPPERmRatBN7.2
Rnor_6.01215,746,376 - 215,747,058NCBIRnor6.0
Rnor_5.01222,641,195 - 222,641,877UniSTSRnor5.0
RGSC_v3.41202,824,897 - 202,825,579UniSTSRGSC3.4
Celera1195,350,068 - 195,350,750UniSTS
Cytogenetic Map1q41UniSTS
H19  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,730,845 - 197,730,993 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,552 - 215,744,699NCBIRnor6.0
Rnor_5.01222,639,371 - 222,639,518UniSTSRnor5.0
RGSC_v3.41202,823,073 - 202,823,220UniSTSRGSC3.4
Celera1195,348,244 - 195,348,391UniSTS
Cytogenetic Map1q41UniSTS
H19  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr81207,160,272 - 207,160,914 (+)Marker Load Pipeline
mRatBN7.21197,730,795 - 197,731,437 (+)MAPPERmRatBN7.2
Rnor_6.01215,744,502 - 215,745,143NCBIRnor6.0
Rnor_5.01222,639,321 - 222,639,962UniSTSRnor5.0
RGSC_v3.41202,823,023 - 202,823,664UniSTSRGSC3.4
Celera1195,348,194 - 195,348,835UniSTS
Cytogenetic Map1q41UniSTS
UniSTS:532168  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21197,731,774 - 197,731,908 (+)MAPPERmRatBN7.2
Rnor_6.01215,745,481 - 215,745,614NCBIRnor6.0
Rnor_5.01222,640,300 - 222,640,433UniSTSRnor5.0
Celera1195,349,173 - 195,349,306UniSTS
Cytogenetic Map1q41UniSTS


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
hemolymphoid system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
sensory system
visual system
7 1 18 22 23 84 51 11 21 26 32 6 6

Sequence


Ensembl Acc Id: ENSRNOT00000102917   ⟹   ENSRNOP00000085212
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1197,730,698 - 197,733,134 (-)Ensembl
RefSeq Acc Id: NR_027324
RefSeq Status: VALIDATED
Type: NON-CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81207,160,175 - 207,162,851 (-)NCBI
mRatBN7.21197,730,698 - 197,733,374 (-)NCBI
Rnor_6.01215,744,404 - 215,747,080 (-)NCBI
Rnor_5.01222,639,223 - 222,641,899 (-)NCBI
RGSC_v3.41202,822,925 - 202,825,601 (-)RGD
Celera1195,348,096 - 195,350,772 (-)RGD
Sequence:
Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2775 AgrOrtholog
BioCyc Gene G2FUF-56903 BioCyc
Ensembl Genes ENSRNOG00000062678 Ensembl
NCBI Gene H19 ENTREZGENE
PhenoGen H19 PhenoGen
RatGTEx ENSRNOG00000062678 RatGTEx
RNAcentral URS000075C4C4 RNACentral
  URS0000CD0288 RNACentral


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2022-06-09 H19  H19 imprinted maternally expressed transcript  H19  H19, imprinted maternally expressed transcript (non-protein coding)  Name changed 629549 APPROVED
2022-06-02 H19  H19, imprinted maternally expressed transcript (non-protein coding)  H19  H19, imprinted maternally expressed transcript (non-protein coding)  Data merged from RGD:149736239 737654 PROVISIONAL
2021-08-09 H19  H19, imprinted maternally expressed transcript (non-protein coding)      Symbol and Name status set to provisional 45752 PROVISIONAL
2011-01-11 H19  H19, imprinted maternally expressed transcript (non-protein coding)  H19  H19, imprinted maternally expressed transcript  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2010-04-20 H19  H19, imprinted maternally expressed transcript  H19  H19 fetal liver mRNA  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-05-07 H19  H19 fetal liver mRNA  H19_mapped  H19 fetal liver mRNA (mapped)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2005-11-17 H19_mapped  H19 fetal liver mRNA (mapped)      Symbol and Name updated 1556543 APPROVED
2002-06-10 H19  H19 fetal liver mRNA      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_expression expressed abundantly in both extraembryonic and fetal tissues 61489
gene_expression expression in skeletal muscle correlated with nonproliferative, actin-positive muscle cells 61489
gene_expression expression temporally and spatially regulated in the prenatal blood vessel with initial loss of expression in the inner smooth muscle layers adjacent to the lumen 61489